Kymera Therapeutics
KYMR
Market cap $3.06B

46.96 USD

-0.33

0.70%

At close Jun 13, 4:00 PM EDT

After hours

46.01

-0.95

2.02%

1 day

-0.70%

5 days

-1.98%

1 month

50.80%

3 months

40.39%

6 months

11.46%

Year to date

14.84%

1 year

34.67%

5 years

41.19%

10 years

41.19%

About: Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

Employees: 208

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

19% more call options, than puts

Call options by funds: $7.84M | Put options by funds: $6.59M

11% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 57

1.38% more ownership

Funds ownership: 110.73% [Q4 2024] → 112.12% (+1.38%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 9 [Q4 2024] → 9 (+0) [Q1 2025]

4% less funds holding

Funds holding: 180 [Q4 2024] → 172 (-8) [Q1 2025]

23% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 30

31% less capital invested

Capital invested by funds: $2.89B [Q4 2024] → $2B (-$890M) [Q1 2025]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$44

6%

downside

Avg. target

$61

29%

upside

High target

$79

68%

upside

7 analyst ratings

6 positive

86%

1 neutral

14%

0 negative

0%

B. Riley Securities Kalpit Patel	28%upside $60	Buy Upgraded	3 Jun 2025
Morgan Stanley James Quigley	68%upside $79	Overweight Upgraded	3 Jun 2025
JP Morgan Eric Joseph	36%upside $64	Overweight Maintained	3 Jun 2025
Stifel Alex Thompson	17%upside $55	Buy Reinstated	20 May 2025
UBS Eliana Merle	49%upside $70	Buy Maintained	13 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about KYMR published over the past 30 days

Analysts Can't Get Enough of These Little-Known Biopharma Stocks

The biopharmaceuticals industry is both exciting and risky for investors. Many leading growth stocks in the U.S. market are found in this sector, due to the significant rallies that biopharmaceutical companies experience when a key positive trial result is announced or an important drug receives government approval.

Analysts Can't Get Enough of These Little-Known Biopharma Stocks

Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial

Shares of the biotech Kymera Therapeutics are up 50% since Monday.

Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial

Zacks Investment Research

Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug

KYMR jumps after KT-621 phase I data beats expectations, matching or topping Dupixent on key biomarkers in Th2 diseases.

Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug

Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data

Kymera Therapeutics' KT-621 demonstrated strong proof-of-concept as an oral STAT6 degrader, showing biologic-like efficacy in phase 1 healthy volunteer data. Results from phase 1b BroADen study, using KT-621 to target patients with moderate-to-severe atopic dermatitis, expected Q4 of 2025. Robust pipeline in place, including a Sanofi partnership on KT-474 and a new IRF5 degrader, diversifies its immunology targeting market opportunity.

Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025

Company to host video webcast at 8:00 a.m. ET on Monday, June 2, 2025 Company to host video webcast at 8:00 a.m. ET on Monday, June 2, 2025

Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference

Kymera Therapeutics: Intriguing Degradation Thesis, But A Bit Powder Puff

I'm downgrading Kymera to 'Hold' due to slow clinical progress, pipeline uncertainty, and lack of near-term catalysts despite strong cash position. Kymera's unique focus on immunology with oral protein degraders offers potential, but faces entrenched competitors and unproven clinical efficacy. Sanofi's advancement of KT-474 is positive, but may be more about testing protein degradation's threat to Dupixent than a strong endorsement.

Kymera Therapeutics: Intriguing Degradation Thesis, But A Bit Powder Puff

Kymera Therapeutics, Inc. (KYMR) Q1 2025 Earnings Call Transcript

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Justine Koenigsberg - Vice President of Investor Relations Nello Mainolfi - Founder, President & Chief Executive Officer Jared Gollob - Chief Medical Officer Veronica Campbell - Senior Director of Immunology Conference Call Participants Jeet Mukherjee - BTIG Marc Frahm - TD Cowen Eliana Merle - UBS Securities Sudan Loganathan - Stephens Vikram Purohit - Morgan Stanley Eric Joseph - JPMorgan Faisal Khurshid - Leerink Partners Michael Schmidt - Guggenheim Andy Chen - Wolfe Research Kalpit Patel - B. Riley Justine Koenigsberg Good morning and welcome to Kymera's Immunology Innovation Day, our virtual event to introduce our next immunology program, IRF5.

Kymera Therapeutics, Inc. (KYMR) Q1 2025 Earnings Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™